Saturday, June 07, 2025 11:55:27 PM
As to how and why CVS is back with AMRN Vascepa preferred, and generics are excluded, maybe the following factors play a part. An update from me:
1) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA OCI in Beltsville, Md
2) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA Commisioner, Silver Spring, Md
3) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FTC Chairman, Washington, D.C.
4) On ~ 6/4/2025, a 3.5 lb package of documents was shipped to the Solicitor General, Washington, D.C., delivery on 6/5/2025. We arrived in Philadelphia on 6/6/2025 for birthday of friend, return home tomorrow, 6/8/2025.
In brief, each of above included a 5-page summary letter of the package of documents, followed by a) photocopies of the entire AMRN shareholder Petition for Writ of Certiorari, b) a notation that no Court in the Federal Judiciary had rendered a judgment accompanied by a rational opinion discussing the evidence of two generics' fraud set forth in the Petition, c) a full photocopy of Hazel-Atlas, 322 U.S. 238(1944), d) a paragraph comparing the fraud on the Courts in Hazel-Atlas, 322 U.S. at 240-243, with the fraud on the Courts set forth in the above Petition,I.e., fabricated evidence and pages 61A-62A of the Petition, e) a paragraph observing that 2 generics had not asked the Nevada District Court to correct her opinion as mistaken with resulting opinion that lack of such action led to conclusion of a deliberate intent to deceive the Courts, and f) a paragraph describing OCI's existence coupled with opinion that FDA Commissioner should withdraw approval of both generics' ANDAs in light of above fraud, consistent with FDA Compliance Policy Guide(CPG) 120.100, Hazel-Atlas, and progeny of 18 U.S.C. 1001, g) a photocopy of 104 F. 4th, h) photocopies of Hikma's Petition for Writ of Certiorari filed 2/2025 together with Amarin's Oppostion filed 5/15/2025 and Hikma 6/2025 reply.
We have NO information whether any Federal agencies have acted in any manner pursuant to information they received above. We will explore further on our return home, likely tomorrow.
1) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA OCI in Beltsville, Md
2) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FDA Commisioner, Silver Spring, Md
3) FedEx notified us, 5/21/2025, that a 3.5 lb package of documents had been delivered to the FTC Chairman, Washington, D.C.
4) On ~ 6/4/2025, a 3.5 lb package of documents was shipped to the Solicitor General, Washington, D.C., delivery on 6/5/2025. We arrived in Philadelphia on 6/6/2025 for birthday of friend, return home tomorrow, 6/8/2025.
In brief, each of above included a 5-page summary letter of the package of documents, followed by a) photocopies of the entire AMRN shareholder Petition for Writ of Certiorari, b) a notation that no Court in the Federal Judiciary had rendered a judgment accompanied by a rational opinion discussing the evidence of two generics' fraud set forth in the Petition, c) a full photocopy of Hazel-Atlas, 322 U.S. 238(1944), d) a paragraph comparing the fraud on the Courts in Hazel-Atlas, 322 U.S. at 240-243, with the fraud on the Courts set forth in the above Petition,I.e., fabricated evidence and pages 61A-62A of the Petition, e) a paragraph observing that 2 generics had not asked the Nevada District Court to correct her opinion as mistaken with resulting opinion that lack of such action led to conclusion of a deliberate intent to deceive the Courts, and f) a paragraph describing OCI's existence coupled with opinion that FDA Commissioner should withdraw approval of both generics' ANDAs in light of above fraud, consistent with FDA Compliance Policy Guide(CPG) 120.100, Hazel-Atlas, and progeny of 18 U.S.C. 1001, g) a photocopy of 104 F. 4th, h) photocopies of Hikma's Petition for Writ of Certiorari filed 2/2025 together with Amarin's Oppostion filed 5/15/2025 and Hikma 6/2025 reply.
We have NO information whether any Federal agencies have acted in any manner pursuant to information they received above. We will explore further on our return home, likely tomorrow.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
